PROM1 and glioblastoma: Given the important roles of SOX2 and CD133 in GBM stemness and plasticity [4, 12, 13, 30], we studied the relationship between the level of expression of these putative stem cell markers and clinical outcomes in patients with GBM to test the hypothesis that GBM stem cells may have a role in response to therapy.